Special Issues

Special Issue Title: Contemporary management of Heart Failure with Reduced Ejection Fraction: Current challenges and future perspectives

· Print Special Issue Flyer

· Deadline for manuscript submissions:  1 March 2021

Special Issue Editor

Guest Editor

Asst. Prof. Alexandros Briasoulis
Department of Clinical Therapeutics, Faculty of Medicine, National and Kapodistrian University of Athens, Greece
Visiting Assistant Professor of Medicine
Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, USA

Website | E-Mail

Interests: Heart Failure, LVAD, Heart Transplant, Hypertension

Special Issue Information

Dear Colleagues,

    Heart failure (HF) is a common clinical syndrome associated with a mortality rate that varies with the severity of disease and can be modified by the administration of appropriate medical and device therapy. HF with reduced ejection fraction (with LVEF ≤40 percent, HFrEF) is associated with unacceptably high rates of morbidity, mortality and hospital readmissions despite advances in treatment of acute coronary syndrome and approval of novel medical and device therapies. Recent studies suggest that the benefit of a comprehensive "quadruple" regimen including an angiotensin receptor-neprilysin inhibitor, a sodium-glucose cotransporter 2 inhibitor), a mineralocorticoid receptor antagonist and a beta-blocker is substantially greater than previously used simpler regimens. The care of patients with HFrEF is complicated and on top of medical and device therapies includes management of the cause of HF and associated conditions, monitoring, preventative care, care coordination, education and support for HF self-management cardiac rehabilitation, and palliative care. However, a major challenge in the management of HFrEF is the accurate identification of those patients who have a poor prognosis and who would therefore be most likely to benefit from intensive medical therapy and/or cardiac transplantation.


HFrEF has an increasing incidence, prevalence, readmission rates and high cost of care. Recent advances in the field are gradually incorporated into daily practice and their impact on patient outcomes and health-care utilization remains to be seen. In light of the recent advances and the existing challenges in the management of patients with HFrEF, we introduce this series of concise reviews that will focus on the contemporary management of these patients and explore the multiple aspects of their care.


We would like to invite experts in the field of HFrEF to write comprehensive reviews (3000 to 5000 words) covering the following topics:

-Contemporary pharmacologic therapies for Heart Failure with Reduced Ejection Fraction

-Management of arrhythmias, conduction system diseases and risk of sudden cardiac death in Heart Failure with Reduced Ejection Fraction

-Pulmonary Hypertension in Left Sided Heart Disease

-Chronic disease management in Heart Failure with Reduced Ejection Fraction: Focus on remote monitoring and telemedicine

-Contemporary management of patients with end-stage Heart Failure: current challenges and future perspectives.

Asst. Prof. Alexandros Briasoulis

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.


Heart failure with reduced ejection fraction (HFrEF); Contemporary management; Pharmacologic therapies; Hearlth care; Chronic disease management

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
Chronic disease management in heart failure: focus on telemedicine and remote monitoring
Paulino Alvarez, Alex Sianis, Jessica Brown, Abbas Ali, Alexandros Briasoulis
Reviews in Cardiovascular Medicine    2021, 22 (2): 403-413.   DOI: 10.31083/j.rcm2202046
Abstract770)   HTML99)    PDF(pc) (1198KB)(824)       Save
In the context of the COVID-19 pandemic, many barriers to telemedicine disappeared. Virtual visits and telemonitoring strategies became routine. Evidence is accumulating regarding the safety and efficacy of virtual visits to replace in-person visits. A structured approach to virtual encounters is recommended. Telemonitoring includes patient reported remote vital sign monitoring, information from wearable devices, cardiac implantable electronic devices and invasive remote hemodynamic monitoring. The intensity of the monitoring should match the risk profile of the patient. Attention to cultural and educational barriers is important to prevent disparities in telehealth implementation.
Related Articles | Metrics
Contemporary management of heart failure patients with reduced ejection fraction: the role of implantable devices and catheter ablation
Catrin Sohrabi, Syed Ahsan, Alexandros Briasoulis, Emmanuel Androulakis, Gerasimos Siasos, Neil T Srinivasan, Nikolaos Papageorgiou
Reviews in Cardiovascular Medicine    2021, 22 (2): 415-428.   DOI: 10.31083/j.rcm2202047
Abstract259)   HTML25)    PDF(pc) (1145KB)(511)       Save
Heart failure (HF) is a complex clinical syndrome characterised by significant morbidity and mortality worldwide. Evidence-based therapies for the management of HF include several well-established neurohormonal antagonists and antiarrhythmic drug therapy to mitigate the onset of cardiac arrhythmia. However, the degree of rate and rhythm control achieved is often suboptimal and mortality rates continue to remain high. Implantable cardioverter-defibrillators (ICDs), cardiac resynchronization (CRT), and combined (CRT-D) therapies have emerged as integral and rapidly expanding technologies in the management of select patients with heart failure with reduced ejection fraction (HFrEF). ICDs treat ventricular arrhythmia and are used as primary prophylaxis for sudden cardiac death, while CRT resynchronizes ventricular contraction to improve left ventricular systolic function. Left ventricular assist device therapy has also been shown to provide clinically meaningful survival benefits in patients with advanced HF, and His-bundle pacing has more recently emerged as a safe, viable, and promising pacing modality for patients with CRT indication. Catheter ablation is another important and well-established strategy for managing cardiac arrhythmia in HF, demonstrating superior efficacy when compared with antiarrhythmic drug therapy alone. In this article, we provide a comprehensive and in-depth evaluation of the role of implantable devices and catheter ablation in patients with HFrEF, outlining current applications, recent advances, and future directions in practice.
Related Articles | Metrics
Transcatheter mitral valve repair with MitraClip in patients with pulmonary hypertension: hemodynamic and prognostic perspectives
Alessandro Mandurino-Mirizzi, Lorenzo Tua, Luca Arzuffi, Andrea Demarchi, Alberto Somaschini, Georgios Tournas, Gabriele Crimi, Emmanuel Androulakis, Alexandros Briasoulis, Stefano Cornara
Reviews in Cardiovascular Medicine    2021, 22 (1): 33-38.   DOI: 10.31083/j.rcm.2021.01.214
Abstract405)   HTML49)    PDF(pc) (204KB)(481)       Save
Transcatheter mitral valve repair with MitraClip has emerged as a possible therapeutic option for patients with severe mitral regurgitation (MR) with high risk for surgical valve repair. MitraClip intervention has demonstrated to improve haemodynamics and clinical outcomes in selected patients in observational and randomized studies. Preoperative pulmonary hypertension (PH) is known to affect prognosis in patients undergoing surgical mitral valve intervention. The aim of the present review is to discuss the available literature focused on the haemodynamic and clinical effects of MitraClip in patients with severe MR and PH.
Related Articles | Metrics
Impact of mechanical circulatory support on donor heart allocation: past, present, and future
Robert T. Tatum, H. Todd Massey, Vakhtang Tchantchaleishvili
Reviews in Cardiovascular Medicine    2021, 22 (1): 25-32.   DOI: 10.31083/j.rcm.2021.01.230
Abstract285)   HTML43)    PDF(pc) (119KB)(556)       Save
The United Network for Organ Sharing (UNOS) recently revised its heart allocation policy to address numerous shortcomings of the previous system. Implemented in 2018, the changes sought to reduce waiting list mortality, clearly define urgency status based on objective physiologic variables, decrease exemption requests, and introduce geographic modifications to ensure organ distribution favors the highest urgency candidates. In large part, UNOS policy revisions were driven by the growing use of continuous flow left ventricular assist devices (CF-LVADs) and the relevant device complications that led to an unacceptably high number of status exemptions. The new 6-tiered system assigns a comparatively lower urgency status to patients supported on CF-LVADs and higher urgency to patients supported on short-term mechanical circulatory assist (MCA) such as extracorporeal membrane oxygenation (ECMO) and intraaortic balloon pump (IABP) counterpulsation. LVAD use as bridge to transplant (BTT) therapy increased steadily throughout the preceding decade due to technological improvements and increased physician familiarity, but the recent policy changes introduce incentives for physicians to withhold this life-saving therapy in order to achieve higher urgency status for their patients. This paper will explore the technological evolution of MCA and the pertinent clinical trials that have led to their FDA approval as BTT and destination therapy. A review of the inception and development of the donor allocation system will be provided before examining available post-policy outcome data. Finally, we will highlight successes and shortcomings of the implemented changes before commenting on areas to potentially expand upon the existing policy.
Related Articles | Metrics

Current Issue

  • Volume 22, Issue 3